A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease. Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or in the patient’s home by a healthcare professional, caregiver, or directly by the patient themselves. Our innovative technology platform is supported by two in-house, commercial scale Current Good Manufacturing Practice (“CGMP”) manufacturing facilities.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 389M | 389M | 291M | 51M | 0 | 0 |
| Net Income | 205M | 205M | 89M | 11M | -140M | -70M |
| EPS | $6.84 | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
| Free Cash Flow | 189M | 189M | 119M | 77M | -154M | -116M |
| ROIC | 23.8% | 14.9% | 7.1% | -11.4% | -25.1% | -15.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.01 | - | 0.02 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 161M | 161M | 66M | -110M | -145M | -145M |
| Operating Margin | 41.5% | 41.5% | 22.6% | -216.2% | - | - |
| ROE | 16.8% | 18.9% | 10.3% | - | -25.1% | -15.7% |
| Shares Outstanding | 30M | 30M | 30M | 28M | 25M | 22M |
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 51M | 291M | 389M | 389M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 28M | 42M | 46M | 54M | 58M | 58M |
| SG&A | 40M | 78M | 98M | 114M | 147M | 147M |
| EBIT | -145M | -145M | -110M | 66M | 161M | 161M |
| Op. Margin | N/A | N/A | -216.2% | 22.6% | 41.5% | 41.5% |
| Net Income | -70M | -140M | 11M | 89M | 205M | 205M |
| Net Margin | N/A | N/A | 21.6% | 30.7% | 52.6% | 52.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -15.7% | -25.1% | -11.4% | 7.1% | 14.9% | 23.8% |
| ROE | -15.7% | -25.1% | N/A | 10.3% | 18.9% | 16.8% |
| ROA | -14.8% | -23.6% | 1.6% | 9.5% | 17.1% | 15.4% |
| Cash Flow | ||||||
| Op. Cash Flow | -48M | -101M | 89M | 123M | 201M | 201M |
| Free Cash Flow | -116M | -154M | 77M | 119M | 189M | 189M |
| Owner Earnings | -66M | -138M | 36M | 52M | 115M | 115M |
| CapEx | 68M | 53M | 12M | 4.2M | 12M | 12M |
| Maint. CapEx | 2.8M | 4.1M | 13M | 22M | 31M | 31M |
| Growth CapEx | 66M | 49M | 0 | 0 | 0 | 0 |
| D&A | 2.8M | 4.1M | 13M | 22M | 31M | 31M |
| CapEx/OCF | N/A | N/A | N/A | 3.4% | 5.9% | 5.9% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 15M | 33M | 40M | 49M | 55M | 55M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -771M | -532M | -882M | -935M | -1.3B | -487M |
| Cash & Equiv. | 341M | 162M | 358M | 345M | 496M | 496M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | 9.3M |
| Debt/Equity | 0.01 | 0.02 | N/A | 0.01 | 0.01 | 0.01 |
| Interest Coverage | -97.3 | N/A | N/A | N/A | N/A | N/A |
| Equity | 594M | 522M | N/A | 946M | 1.2B | 1.2B |
| Total Assets | 626M | 558M | 818M | 1.1B | 1.3B | 1.3B |
| Total Liabilities | 33M | 36M | N/A | 109M | 114M | 114M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -141M | -281M | -270M | -181M | 24M | 24M |
| Working Capital | 417M | 355M | 555M | 640M | 922M | 922M |
| Current Assets | 442M | 384M | 588M | 742M | 1.0B | 1.0B |
| Current Liabilities | 26M | 29M | 33M | 102M | 103M | 103M |
| Per Share Data | ||||||
| EPS | -3.13 | -5.49 | 0.39 | 3.00 | 6.84 | 6.84 |
| Owner EPS | -2.97 | -5.41 | 1.29 | 1.76 | 3.84 | 3.84 |
| Book Value | 26.71 | 20.48 | N/A | 31.84 | 40.73 | 40.73 |
| Cash Flow/Share | -2.16 | -3.94 | 3.17 | 4.15 | 6.71 | 7.88 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 22.2M | 25.5M | 28.0M | 29.7M | 29.9M | 29.9M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | 327.6 | 53.1 | 36.9 | 39.1 |
| P/FCF | N/A | N/A | 46.5 | 39.7 | 40.0 | 42.4 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 46.6 |
| Price/Book | 2.6 | 3.7 | N/A | 5.0 | 6.2 | 6.6 |
| Price/Sales | N/A | N/A | 57.0 | 17.3 | 12.9 | 20.6 |
| FCF Yield | -7.5% | -7.9% | 2.2% | 2.5% | 2.5% | 2.4% |
| Market Cap | 1.6B | 1.9B | 3.6B | 4.7B | 7.6B | 8.0B |
| Avg. Price | 64.71 | 67.78 | 103.11 | 169.53 | 167.94 | 267.41 |
| Year-End Price | 69.78 | 76.00 | 127.76 | 159.29 | 252.17 | 267.41 |
Krystal Biotech, Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Krystal Biotech, Inc. trades at 39.1x trailing earnings, compared to its 15-year median P/E of 45.0x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 41.4x vs a median of 40.0x. At current prices, the estimated annualized return to fair value is +83.8%.
Krystal Biotech, Inc. (KRYS) has a current P/E ratio of 39.1, compared to its historical median P/E of 45.0. The stock is currently considered Fair based on its historical valuation range.
Krystal Biotech, Inc. (KRYS) has a 5-year average return on invested capital (ROIC) of -6.0%. This is below average and may indicate limited pricing power.
Krystal Biotech, Inc. (KRYS) has a market capitalization of $8.0B. It is classified as a mid-cap stock.
Krystal Biotech, Inc. (KRYS) does not currently pay a regular dividend.
Based on historical P/E analysis, Krystal Biotech, Inc. (KRYS) appears fair. The current P/E of 39.1 is 13% below its historical median of 45.0. The estimated fair value CAGR (P/E method) is 51.1%.
Krystal Biotech, Inc. (KRYS) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Krystal Biotech, Inc. (KRYS) reported annual revenue of $389 million in its most recent fiscal year, based on SEC EDGAR filings.
Krystal Biotech, Inc. (KRYS) has a net profit margin of 52.6%. This is a strong margin indicating high profitability.
Krystal Biotech, Inc. (KRYS) generated $189 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Krystal Biotech, Inc. (KRYS) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Krystal Biotech, Inc. (KRYS) reported earnings per share (EPS) of $6.84 in its most recent fiscal year.
Krystal Biotech, Inc. (KRYS) has a return on equity (ROE) of 18.9%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 5 years of financial data for Krystal Biotech, Inc. (KRYS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Krystal Biotech, Inc. (KRYS) has a book value per share of $40.73, based on its most recent annual SEC filing.